ClinicalTrials.gg
RecruitingNCT07372989HAF ILDUpdated Oct 13, 2026

Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease

A Phase 1 interventional study of Matrix in Lung Diseases, Interstitial, sponsored by Maule Stem Cell Research Institute, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Maule Stem Cell Research Institute, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Updated Oct 13, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 201 studies in Lung Diseases, Interstitial with a site in United States — 67 open to participants now, 83 under way, 19 of them phase 3. Lung Diseases, Interstitial · United States.

Planned enrollment
71st of 138
50 · median 53
Started
2026
with 25 others
Phase 1
12 of 201
4 open now
Primary completion
2028-06
later than 45 of 82 live
Registered
185th of 201
by date

Among the 201 studies in Lung Diseases, Interstitial with a site in United States, this one is the 71st largest by planned enrollment of the 138 interventional ones that give a count, is one of 26 that started in 2026, is one of 12 in phase 1, reaches primary completion later than 45 of the 82 other live ones, and was the 185th registered.

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.

Browse Lung Diseases, Interstitial studies →

Open to participants now

67 of the 201 studies in Lung Diseases, Interstitial with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 67 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 201 studies in Lung Diseases, Interstitial with a site in United States, or all of them as a file.
02

Study summary

This is a Phase I, pilot clinical trial designed to evaluate the safety and exploratory efficacy of nebulized diluted amniotic fluid, Matrix (HAF-Matrix) in adults with interstitial lung disease (ILD). ILDs are progressive fibrotic disorders characterized by aberrant wound-healing responses, chronic inflammation, and dysregulated fibroblast activation, ultimately leading to impaired gas exchange and respiratory failure. Current treatments, such as antifibrotic agents (pirfenidone and nintedanib), slow disease progression but do not reverse existing fibrosis or restore lung function. This pilot study will generate critical safety and preliminary efficacy data to inform future larger-scale trials and optimize dosing strategies for nebulized HAF-based therapeutics in ILD.

Read the detailed description

This pilot study will generate critical safety and preliminary efficacy data to inform future larger-scale trials and optimize dosing strategies for nebulized EV-based therapeutics in ILD.

Two-part seamless design:

Dose Escalation Approach with a 3+3 (Cohort A = 3, Cohort B = 3) Total of 6 Participants Design with Staggered Dosing:

1. Cohort Enrollment and Initial Dosing

  • At each prespecified dose level, three (3) subjects will be enrolled and dosed.

The first subject in each cohort will be dosed initially, followed by the second and third subjects according to planned staggered intervals, ensuring careful monitoring of early safety signals.

Post 3x3 run-in phase, The Phase 1(open label) will begin:

  • 2 Cohorts of 22 participants per cohort:
  • Doses 1.0 ml and 1.5 ml of Matrix via mesh nebulizer:

Cohort A, n=22: 1×10\^9 particles Cohort B, n=22: 1×10\^12 particles (Dose range anchored to inhaled-EV clinical experience.)

03

Conditions studied

  • Lung Diseases, Interstitial

Keywords

  • Interstitial Lung Disease (ILD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to participate in this study, a patient MUST:

  • Provide written .
  • Subjects age > 40 and \< 90 years at the time of signing the Informed Consent Form.
  • Have a clinical diagnosis of ILD prior to screening in accordance with the guidelines of the American Thoracic Society/European Respiratory Society.
  • FVC ≥ 45% predicted and DLCO ≥30% (corrected for but not alveolar volume).
  • Resting SpO₂ ≥ 92% on ≤ 3 L/min O₂.
  • RVSP \< 50 mmHg, as documented by Doppler echo or right heart catheterization.
  • Female subjects must be surgically sterile or (>1 year).

Exclusion criteria

Exclusion Criteria:

In order to participate in this study, a patient MUST NOT:

  • CT and/or surgical lung results inconsistent with the diagnosis of IPF.
  • Inability to perform any of the assessments required for endpoint analysis (report safety or tolerability concerns, perform PFTs or CT, undergo blood draws, read and respond to questionnaires.)
  • Currently receiving (or received within four weeks of screening) any medication, treatment, or experimental agents for the treatment of ILD, except for patients receiving non-drug therapies will include oxygen saturation therapy (oxygen supplementation) and pulmonary rehabilitation.
  • Active listing (or expected future listing) for transplant of any organ.
  • abnormal screening laboratory values, including but not limited to: \<8 g/dl, white blood cell count \<3000/mm3, \<80,000/mm3, > 1.5, , alanine transaminase, or alkaline phosphatase > 2 times , total > 1.5 mg/dl.
  • Serious comorbid illness that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study. Including, but not limited to: , advanced liver or renal failure, class III/IV congestive heart failure, myocardial infarction, unstable angina, or cardiac revascularization within the last six months, or severe obstructive ventilatory defect.
  • Any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study.
  • Be an organ transplant recipient.
  • Have a clinical history of within 2.5 years (i.e., patients with prior malignancy must be disease free for 2.5 years), except curatively treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma.
  • Have a non-pulmonary condition that limits lifespan to \< 1 year.
  • Have a history of drug or alcohol abuse within the past 24 months.
  • Be serum positive for HIV, hepatitis BsAg or Viremic .
  • Be currently participating (or participated within the previous 30 days) in an therapeutic or device trial.
  • Be a female who is pregnant, nursing, or of while not practicing effective methods. Female patients must undergo a blood or urine pregnancy test at screening and within 36 hours prior to injection.
  • Female subjects must have an FSH \< 25.8 IU/L
  • Subject with to dimethyl sulfoxide (DMSO)
  • Saturated oxygen (SpO2 of \< 93% (room air [sea level] at rest). SpO2 of \< 88% (room air [>5,000 feet above sea level (1524 meters) at rest).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Cohort A

    1.0 mL of Matrix (Exosomes)

    Biological: Matrix

  • Experimental
    Cohort B

    1.5 mL of Matrix (Exosomes)

    Biological: Matrix

Interventions

  • BiologicalMatrix

    Allogeneic Human Amniotic Fluid (HAF) using Aerogen Solo (Ultra Nebulizer)

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Outcome Measure Description: Incidence of treatment-emergent serious adverse events (TE-SAEs) in participants receiving nebulized Matrix (HAF) therapy. Unit of Measure: Number of participants with ≥1 TESAE

    Time frame: From first dose through study completion (approximately 13 months)

Secondary outcomes

  1. Change in observed forced vital capacity (FVC) .

    Change From Baseline in Forced Vital Capacity (FVC) Outcome Measure Description: Change from baseline in forced vital capacity (FVC) as assessed by pulmonary function testing. Unit of Measure: Liters (L) or percent predicted (%)

    Time frame: Baseline to 6 months.

Other outcomes

  1. Forced expiratory volume in 1 second (FEV1).

    Change From Baseline in Forced Expiratory Volume in 1 Second (FEV₁) Outcome Measure Description: Change from baseline in forced expiratory volume in 1 second (FEV₁) as assessed by pulmonary function testing. Unit of Measure: Liters (L) or percent predicted (%)

    Time frame: Baseline to 6 months

07

Study locations

1 of 1 sites recruiting
  • Maule Stem Cell Research Institute
    Venice, Florida 34292, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2026 (actual). Primary completion is estimated for Jun 2028, 28 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2027 → Jun 2028, on Oct 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2026
First posted
Jan 28, 2026
StartActual
Feb 23, 2026
Primary completionEst.
Jun 2028was Jun 2027
CompletionEst.
Oct 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 1, 2027→Jun 2028
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Jun 1, 2027→Jun 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07372989
Lead sponsor
Maule Stem Cell Research Institute, Inc.
Responsible party
Sponsor
First posted
Jan 28, 2026
Start date
Feb 23, 2026
Primary completion
Jun 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Kendra Hekter
Contact
kendra@mauleresearch.org
941-949-2474
Bonnie Vasquez
Contact
bonnie@mauleresearch.org
941-949-2474
Cynthia S. Maule, M.D.
principal investigator · Maule Stem Cell Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion